ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005


The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2022 and some content may be unavailable. To unlock all content for 2022, please visit the archives.

Abstract: TH-PO291

Using the Seraph® 100 Microbind Affinity Blood Filter Under Slow Flow Conditions Through a Non-Dialysis Catheter

Session Information

Category: Dialysis

  • 701 Dialysis: Hemodialysis and Frequent Dialysis


  • Seffer, Malin-Theres, Academic Teaching Hospital Braunschweig, Braunschweig, Germany
  • Schmidt, Julius, Medizinische Hochschule Hannover, Hannover, Niedersachsen, Germany
  • Kielstein, Jan T., Academic Teaching Hospital Braunschweig, Braunschweig, Germany

The Seraph® 100 is a single use biomimetic device aimed to remove patogens from the bloodstream, usually operated under blood flow rates of 100 – 350 mL/min, requiring a large bore central line / dialysis catheter. Aim of our study was to evaluate the pressure / blood flow curve in vitro using saline as well as human plasma and to evaluate the usability of the Seraph® 100 in the clinical practice.


Patients and study protocol
Blood plasma was obtained from five voluntary donors during regular therapeutic plasma exchange.

Sham hemofiltation with the Seraph® 100
For all experiments primed a standard hemoperfusion blood tubing system as well as the Seraph® 100 (Exthera Medical, CA, USA) with a total filling volume of about 2200 mL with normal saline (n=5) or with human plasma and connected the hemoperfusion circuit with a 20 cm tri lumen central venous line (2 x 18 G and 1 x 16 G, Certofix® safety trio s720, B.Braun REF: 4167408S-07; Lot: 19D30A8551) that was inserted into a reservoir. The Multifiltrate (Fresenius Medical Care GmbH, Germany) was used to pump the saline through the adsorber. Blood flow was raised in in steps of 10 ml beginning at 20 ml up to 100 ml. Arterial and venous pressure was recorded at the different blood pump speeds.

In two patients the Seraph® 100 in the hemoperfusion circuit of a Multifiltrate (Fresenius Medical Care GmbH, Bad Homburg, Germany), was connected to a five lumen 20 cm catheter (Certofix Safety Quinto S1220, B. Braun, Melsungen, Germany) 1 x 12 G, 1 x 16 G, 3 x 18 G) that was inserted into the right internal jugular vein. Blood flow as well as arterial and venous pressure and TMP were recorded through the 24 h treatment.


All five in vitro runs using either saline and human plasma could be performed without any technical difficulties.


A blood flow rate of 50 mL/mi can be achieved with a 16 G and 18 G vascular access of central lines. Even long treatment hours (up to 25 hours) under low flow conditions to optimize exposure of patient’s blood to the Seraph 100 adsorption media can be achieved.

Relationship between blood pump speed and the arterial as well as venous pressure using saline / plasma.